Maspero JF, Katelaris CH, Busse WW, et al. - Researchers evaluated whether dupilumab (a fully human monoclonal antibody) affords a safe and effective treatment option for patients with uncontrolled, moderate-to-severe asthma with or without self-reported comorbid chronic rhinosinusitis (CRS or non-CRS). This study included 1,902 patients, among these, 382 (20.1%) self-reported CRS. A decline in the annualized severe exacerbation rates was brought about by dupilumab 200 mg/300 mg; which was by 63%/61%, respectively, in patients with CRS, and by 42%/40% in patients without CRS. In both subgroups, dupilumab resulted in improvement in lung function and patient-reported asthma control and quality of life, as well as suppressed type 2 biomarkers in comparison with placebo. In addition, it induced rapid clinical responses, with near-maximal responses seen at the earliest measured time points and maintained at week 52. In the CRS subgroup vs non-CRS subgroup, similar or numerically greater improvements were evident. Based on these findings, the experts concluded dupilumab as an effective treatment option with generally good tolerability in patients with uncontrolled, moderate-to-severe asthma with or without CRS.